Literature DB >> 33082139

FUS contributes to mTOR-dependent inhibition of translation.

Myriam Sévigny1, Isabelle Bourdeau Julien1, Janani Priya Venkatasubramani1, Jeremy B Hui1, Paul A Dutchak1, Chantelle F Sephton2.   

Abstract

The amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)-linked RNA-binding protein called FUS (fused in sarcoma) has been implicated in several aspects of RNA regulation, including mRNA translation. The mechanism by which FUS affects the translation of polyribosomes has not been established. Here we show that FUS can associate with stalled polyribosomes and that this association is sensitive to mTOR (mammalian target of rapamycin) kinase activity. Specifically, we show that FUS association with polyribosomes is increased by Torin1 treatment or when cells are cultured in nutrient-deficient media, but not when cells are treated with rapamycin, the allosteric inhibitor of mTORC1. Moreover, we report that FUS is necessary for efficient stalling of translation because deficient cells are refractory to the inhibition of mTOR-dependent signaling by Torin1. We also show that ALS-linked FUS mutants R521G and P525L associate abundantly with polyribosomes and decrease global protein synthesis. Importantly, the inhibitory effect on translation by FUS is impaired by mutations that reduce its RNA-binding affinity. These findings demonstrate that FUS is an important RNA-binding protein that mediates translational repression through mTOR-dependent signaling and that ALS-linked FUS mutants can cause a toxic gain of function in the cytoplasm by repressing the translation of mRNA at polyribosomes.
© 2020 Sévigny et al.

Entities:  

Keywords:  RNA-binding protein; Torin1; amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease); fragile X mental retardation (FMRP); frontotemporal degeneration (FTD); fused in sarcoma (FUS); mRNA translation; mTORC1; mTORC2; mammalian target of rapamycin (mTOR); neurodegeneration; polyribosome; protein synthesis; rapamycin; ribosome; translation regulation

Mesh:

Substances:

Year:  2020        PMID: 33082139      PMCID: PMC7939483          DOI: 10.1074/jbc.RA120.013801

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

1.  A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.

Authors:  Avinash Patel; Hyun O Lee; Louise Jawerth; Shovamayee Maharana; Marcus Jahnel; Marco Y Hein; Stoyno Stoynov; Julia Mahamid; Shambaditya Saha; Titus M Franzmann; Andrej Pozniakovski; Ina Poser; Nicola Maghelli; Loic A Royer; Martin Weigert; Eugene W Myers; Stephan Grill; David Drechsel; Anthony A Hyman; Simon Alberti
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

2.  S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.

Authors:  Usha Narayanan; Vijayalaxmi Nalavadi; Mika Nakamoto; George Thomas; Stephanie Ceman; Gary J Bassell; Stephen T Warren
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

3.  FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association.

Authors:  Y Feng; D Absher; D E Eberhart; V Brown; H E Malter; S T Warren
Journal:  Mol Cell       Date:  1997-12       Impact factor: 17.970

4.  FUS and TDP43 genetic variability in FTD and CBS.

Authors:  Edward D Huey; Raffaele Ferrari; Jorge H Moreno; Christopher Jensen; Christopher M Morris; Felix Potocnik; Rajesh N Kalaria; Michael Tierney; Eric M Wassermann; John Hardy; Jordan Grafman; Parastoo Momeni
Journal:  Neurobiol Aging       Date:  2011-09-23       Impact factor: 4.673

5.  Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes.

Authors:  Chantelle F Sephton; Can Cenik; Alper Kucukural; Eric B Dammer; Basar Cenik; Yuhong Han; Colleen M Dewey; Frederick P Roth; Joachim Herz; Junmin Peng; Melissa J Moore; Gang Yu
Journal:  J Biol Chem       Date:  2010-11-04       Impact factor: 5.157

6.  A unifying model for mTORC1-mediated regulation of mRNA translation.

Authors:  Carson C Thoreen; Lynne Chantranupong; Heather R Keys; Tim Wang; Nathanael S Gray; David M Sabatini
Journal:  Nature       Date:  2012-05-02       Impact factor: 49.962

7.  Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity.

Authors:  Zachary Monahan; Veronica H Ryan; Abigail M Janke; Kathleen A Burke; Shannon N Rhoads; Gül H Zerze; Robert O'Meally; Gregory L Dignon; Alexander E Conicella; Wenwei Zheng; Robert B Best; Robert N Cole; Jeetain Mittal; Frank Shewmaker; Nicolas L Fawzi
Journal:  EMBO J       Date:  2017-08-08       Impact factor: 11.598

8.  Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.

Authors:  Harro Seelaar; Kirsten Y Klijnsma; Inge de Koning; Aad van der Lugt; Wang Zheng Chiu; Asma Azmani; Annemieke J M Rozemuller; John C van Swieten
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

9.  Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS.

Authors:  Dorothee Dormann; Tobias Madl; Chiara F Valori; Eva Bentmann; Sabina Tahirovic; Claudia Abou-Ajram; Elisabeth Kremmer; Olaf Ansorge; Ian R A Mackenzie; Manuela Neumann; Christian Haass
Journal:  EMBO J       Date:  2012-09-11       Impact factor: 11.598

10.  Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.

Authors:  Caroline Vance; Boris Rogelj; Tibor Hortobágyi; Kurt J De Vos; Agnes Lumi Nishimura; Jemeen Sreedharan; Xun Hu; Bradley Smith; Deborah Ruddy; Paul Wright; Jeban Ganesalingam; Kelly L Williams; Vineeta Tripathi; Safa Al-Saraj; Ammar Al-Chalabi; P Nigel Leigh; Ian P Blair; Garth Nicholson; Jackie de Belleroche; Jean-Marc Gallo; Christopher C Miller; Christopher E Shaw
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

View more
  5 in total

1.  Identification of a novel interaction of FUS and syntaphilin may explain synaptic and mitochondrial abnormalities caused by ALS mutations.

Authors:  Shaakir Salam; Sara Tacconelli; Bradley N Smith; Jacqueline C Mitchell; Elizabeth Glennon; Nikolas Nikolaou; Corinne Houart; Caroline Vance
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.996

2.  A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.

Authors:  Gaël Nicolas; Myriam Sévigny; François Lecoquierre; Florent Marguet; Andréanne Deschênes; Maria Carment Del Pelaez; Sébastien Feuillette; Anaïs Audebrand; Magalie Lecourtois; Stéphane Rousseau; Anne-Claire Richard; Kévin Cassinari; Vincent Deramecourt; Charles Duyckaerts; Anne Boland; Jean-François Deleuze; Vincent Meyer; Jordi Clarimon Echavarria; Ellen Gelpi; Haruhiko Akiyama; Masato Hasegawa; Ito Kawakami; Tsz H Wong; Jeroen G J Van Rooij; John C Van Swieten; Dominique Campion; Paul A Dutchak; David Wallon; Flavie Lavoie-Cardinal; Annie Laquerrière; Anne Rovelet-Lecrux; Chantelle F Sephton
Journal:  Acta Neuropathol Commun       Date:  2022-02-12       Impact factor: 7.801

Review 3.  Proteostasis Deregulation in Neurodegeneration and Its Link with Stress Granules: Focus on the Scaffold and Ribosomal Protein RACK1.

Authors:  Mirco Masi; Alessandro Attanzio; Marco Racchi; Benjamin Wolozin; Sofia Borella; Fabrizio Biundo; Erica Buoso
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

Review 4.  Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease.

Authors:  Pauline A Gelon; Paul A Dutchak; Chantelle F Sephton
Journal:  Front Mol Neurosci       Date:  2022-10-03       Impact factor: 6.261

5.  FUS-ALS mutants alter FMRP phase separation equilibrium and impair protein translation.

Authors:  Nicol Birsa; Agnieszka M Ule; Maria Giovanna Garone; Brian Tsang; Francesca Mattedi; P Andrew Chong; Jack Humphrey; Seth Jarvis; Melis Pisiren; Oscar G Wilkins; Micheal L Nosella; Anny Devoy; Cristian Bodo; Rafaela Fernandez de la Fuente; Elizabeth M C Fisher; Alessandro Rosa; Gabriella Viero; Julie D Forman-Kay; Giampietro Schiavo; Pietro Fratta
Journal:  Sci Adv       Date:  2021-07-21       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.